Abstract
Alterations in the insulin-like growth factor (IGF)-system were evaluated in 16 patients treated with diethylstilboestrol 5 mg 3 times daily. Fasting blood samples were obtained before treatment and after 2 weeks, 1 month and/or 2–3 months on therapy. Insulin-like growth factor (IGF)-I, IGF-II, free IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-2 and IGFBP-3 were measured by radioimmuno-/immunoradiometric-assays. All samples were subjected to Western ligand blotting as well as immunoblotting for IGFBP-3. We observed a significant decrease (percentage of pretreatment levels with 95 confidence intervals of the mean) in IGF-I [2 weeks 63% (49–79); 1 month 56% (44–73); 2–3 months 66% (53–82)], IGF-II [2 weeks 67% (56–80); 1 month 60% (52–68); 2–3 months 64% (55–75)], free IGF-I [2 weeks 29% (19–42); 1 month 25% (18–36); 2–3 months 31% (21–46)], IGFBP-2 [2 weeks 53% (18–156); 1 month 69% (61–78); 2–3 months 66% (57–78)], IGFBP-3 [2 weeks 74% (63–85); 1 month 69% (62–76); 2–3 months 71% (63–80)], as well as IGFBP-3 protease activity [2 weeks 71% (54–95); 1 month 78% (64–94); 2–3 months 71% (54–93)]. Contrary, the plasma levels (percentage of pretreatment levels with 95 confidence intervals of the mean) of IGFBP-1 [2 weeks 250% (127–495); 1 month 173% (138–542); 2–3 months 273% (146–510)] and IGFBP-4 [2 weeks 146% (112–192); 1 month 140% (116–169); 2–3 months 150% (114–198)] increased significantly. While this study confirms previous observations during treatment with oral oestrogens in substitution doses, the reduction in plasma IGF-II, free IGF-I, IGFBP-2 and -3 are all novel findings. A profound decrease in free IGF-I suggests a reduced bioavailability of IGFs from plasma to the tissues. These observations may be of significance to understand the mechanisms of the antitumour effect of diethylstilboestrol in pharmacological doses. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arteaga CJ, Kitten LJ, Coronado EB, Jacobs S Jr. F.C. K., Allred DC and Osborne CK (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84: 1418–1423
Bereket A, Lang CH, Blethen SL, Fan J, Frost RA and Wilson TA (1995) Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 80: 2282–2288
Bishop MC, Selby C and Taylor M (1985) Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine. Br J Urol 57: 542–547
Bowsher RR, Lee W-H, Apathy JM, O’Brien PJ, Ferguson AL and Henry DP (1991) Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids. Endocrinology 128: 805–814
Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW and Potter NR (1977) Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. JAMA 237: 2079–2085
Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR and Rosenfeld RG (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76: 1031–1035
Colletti RB, Roberts JD, Devlin JT and Copeland KC (1989) Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49: 1882–1884
Cotterill AM, Mendel P, Holly JMP, Timmins AG, Camacho-Hubner C, Cwyfan-Hughes S, Ross RMJ, Blum WF and Langford RM (1996) The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1,2 and 3 after elective abdominal surgery. Clin Endocrinol 44: 91–101
Coulson VJ, Wass JAH, Abdulla AF, Cotterill AM and Holly JMP (1991) Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Reg 1: 119–124
Daughaday WH and Rotwein P (1989) Insulin-like growth factors I and II. Peptide messinger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Rev 10: 68–91
Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58: 3353–3361
Fex G, Adielsson G and Mattson W (1981) Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol 97: 109–113
Frost VJ, Helle SI, Lønning PE, van der Stappen JWJ and Holly JMP (1996) Effects of treatment with megestrol acetate, aminoglutethimide or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs) and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 81: 2216–2221
Frystyk J, Skjærbæk C, Støvning RK, Dall R, Bek T and Ørskov H (1999) Measurement of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay. Growth Horm IGF Res 9: P45
Giudice LC, Farrell EM, Pham H, Lamson G and Rosenfeld RG (1990) Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy associated serum protease activity. J Clin Endocrinol Metab 71: 806–816
Haddow A, Watkinson JM and Paterson E (1944) Influence of synthetic oestrogens upon advanced malignant disease. Br Med J 2: 393–398
Hankinson SE, Willett WE, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396
Helle SI, Anker GB, Tally M, Hall K and Lønning PE (1996a) Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Molec Biol 57: 167–171
Helle SI, Holly JMP, Tally M, Hall K, van der Stappen J and Lønning PE (1996b) Influence of treatment with tamoxifen and change in tumour burden on the IGF-system in breast cancer patients. Int J Cancer 69: 335–339
Helle SI, Omsjø IH, Cwyfan-Hughes SC, Holly JMP and Lønning PE (1996c) Effects of oral and parenteral oestrogen replacement therapy on plasma levels of insulin-like growth factors (IGFs) and IGF binding proteins 1 and 3: a crossover study. Clin Endocrinol 45: 727–732
Helle SI, Geisler J, Poulsen JP, Hestdal K, Meadows K, Collins W, Tveit KM, Viste A, Holly JMP and Lønning PE (1998) Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study. Br J Cancer 78: 14–20
Hossenlopp P, Seurin D, Segovia-Quinson B, Lassarre C, Hardouin S and Binoux M (1986) Analysis of serum insulin-like growth factor binding proteins using Western ligand blotting: use of the method of titration of the binding proteins in competitive binding studies. Anal Biochem 154: 138–143
Huynh HT, Tetenes E, Wallace L and Pollak M (1993) In vivoinhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res 53: 1727–1730
Hwa V, Tomasini-Sprenger C, Bermejo AL, Rosenfeld RG and Plymate SR (1998) Characterization of insulin-like growth factor-binding protein-related protein-1 in prostate cells. J Clin Endocrinol Metab 83: 4355–4362
Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J and Frytak S (1981) Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16–21
Jones JI and Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev 16: 3–34
Kam GYW, Leung K-C, Baxter RC and Ho KKY (2000) Estrogens exert route-and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 85: 1918–1922
Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B and Karasik A (1993) Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77: 229–233
Karey KP and Sirbasku DA (1988) Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res 48: 4083–4092
Lassarre C and Binoux M (1994) Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 134: 1254–1262
Lee AV, Darbre P and King RJB (1994) Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol 99: 211–220
Lee AV, Weng C-N, Jackson JG and Yee D (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152: 39–47
Lippman M, Bolan G and Huff K (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601
Lønning PE, Hall K, Aakvaag A and Lien EA (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein 1 in breast cancer patients. Cancer Res 52: 4719–4723
Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen L-M, Mella O and Howell A (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat,
Love RR, Wiebe DA, Newcombe PA and al E (1991) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860–864
Masamura S, Santner SJ, Heitjan DF and Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80: 2918–2925
Molloy CA, May FEB and Westley BR (2000) Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 275: 12565–12571
Müller HL, Oh Y, Gargosky SE, Lehrnbecher T, Hinz RL and Rosenfeld RG (1993) Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J Clin Endocrinol Metab 77: 1113–1119
Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC and Loprinzi CL (1999) Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 54: 117–122
Pratt SE and Pollak MN (1993) Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193–5198
Salahifar H, Baxter RC and Martin JL (2000) Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-betal. Endocrinology 141: 3104–3110
Song RX, McPherson R, Yue W, Wang JP and Santen RJ (2000) Estrogen induces apoptosis in human breast cancer cells adapted to long term estrogen deprivation. Proc Am Assoc Cancer Res 41: 2715
Stewart AJ, Johnson MD, May FEB and Westley BR (1990) Role of the insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265: 21172–21178
Weissberger AJ, Ho KKY and Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement on 24 hour growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72: 374–381
Westley BR and May FEB (1994) Role of the insulin-like growth factors in steroid modulated proliferation. J Steroid Bioch, Molec Biol 51: 1–9
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Helle, S., Geisler, J., Anker, G. et al. Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer. Br J Cancer 85, 147–151 (2001). https://doi.org/10.1054/bjoc.2001.1871
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1871
Keywords
This article is cited by
-
Insulin-like growth factors and neoplasia
Nature Reviews Cancer (2004)